PhD student Morten Svarer Hansen signs final GCP monitor report
The signature paves the way for publishing data on the effects of 52 weeks of treatment with semaglutide on human bone
At KMEB/Department of Endocrinology, we do translational science which means that we are involved in both basic and clinical research. Today was one of those days to remember as one of our PhD students put a signature on the final GCP monitor report. GCP stands for Good Clinical Practice and is an internationally agreed set of standards for designing, recording and reporting trials that involve human subjects. This signature paves the way for publishing data on the effects of 52 weeks of treatment with semaglutide on human bone. Semaglutide is a glucagon-like peptide 1 receptor agonist that is normally used in the treatment of type 2 diabetes and severe obesity.